Minimally Invasive Inguinal Lymph Node Dissection Safer for Penile Cancer - Oncology Nurse Advisor A systematic review and meta-analysis compared the perioperative and oncologic outcomes of open versus minimally invasive inguinal lymphadenectomy during penile cancer surgery.

Minimally invasive approaches to inguinal lymph node dissection reduce morbidity without compromising oncologic outcomes in #penilecancer. Presented at #SUO25.

https://bit.ly/45OGsq4

#GUOnc

Renal Dysfunction in RCC With IVC Tumor Thrombus May Be Partially Reversible - Oncology Nurse Advisor Up to 10% of patients with RCC have IVC tumor thrombus that may impair kidney function.

The likely cause of renal dysfunction in patients with #renalCellCarcinoma and IVC tumor thrombus is congestive nephropathy – and it may be reversible with nephrectomy and IVC thrombectomy. Presented at #SUO25, covered by @renalurologynews.bsky.social.

https://bit.ly/49SXMwv

#RCC

#BCG may be less effective in patients who develop metachronous #NMIBC after radical nephrouretectomy for #UTUC. Reported at #SUO25 by Yu Guang Tan, MBBS, of Singapore General Hospital covered by @renalurologynews.bsky.social.
https://bit.ly/4sJXtf5

#bladdercancer #blcsm

Cretostimogene Yields Durable Event-Free Survival in Papillary, BCG-Unresponsive NMIBC - Oncology Nurse Advisor The phase 3, open-label, single arm BOND-003 trial also evaluated cretostimogene in cohort P with papillary-only high-grade NMIBC who failed prior BCG therapy.

Cretostimogene grenadenorepvec prolongs high-grade event-free survival in patients with high-risk, papillary-only #NMIBC that fails to respond to BCG. Mark Tyson, MD of @mayoclinic.org presented at #SUO25, from @renalurologynews.bsky.social.

https://bit.ly/4paeufm

#bladdercancer

#BiotechHangout: Grace Colon, Chris Garabedian, Sam Fazeli, Paul Matteis, Yaron Werber, John Stanford on policy: NDAA provisions, industry trends: $1.85B in biotech financings, $XBI, $LLY’s acquisitive strategy, Fosun+$PFE, confs: #ASH25, #ESMOAsia, #SUO25, obesity data, Endpts 100: bit.ly/4q32CMO

Cretostimogene Grenadenorepvec Shows Efficacy in Papillary-Only, BCG-Unresponsive NMIBC | OncLive Cretostimogene grenadenorepvec shows durable activity in BCG-unresponsive papillary-only NMIBC with no progression to MIBC and favorable tolerability.

Cretostimogene Grenadenorepvec Shows Efficacy in Papillary-Only, BCG-Unresponsive NMIBC @mayoclinic.org #SUO25 #oncology www.onclive.com/view/cretost...

Updated TRITON3 Data Support Rucaparib in BRCA-Mutated mCRPC Regardless of Age | OncLive Rucaparib delivers consistent rPFS benefits across all age groups in BRCA-mutated mCRPC, reinforcing its role as an effective treatment option.

Updated TRITON3 Data Support Rucaparib in BRCA-Mutated mCRPC Regardless of Age @cityofhope.bsky.social #SUO25 #oncology www.onclive.com/view/updated...

Belzutifan Maintains High, Durable Responses in VHL Disease–Associated Neoplasms At 5 Years | OncLive At 48 months, the majority of patients with VHL disease–associated tumors remained in response following treatment with belzutifan.

Belzutifan Maintains High, Durable Responses in VHL Disease–Associated Neoplasms At 5 Years #SUO2025 #SUO25 #kcsm #oncology #medtwitter
www.onclive.com/view/belzuti...

Adjuvant Pembrolizumab Delivers Long-Term Benefits in ccRCC at Increased Risk of Recurrence | OncLive Adjuvant pembrolizumab delivers sustained clinical benefits across ccRCC subgroups with no new long-term safety signals.

Adjuvant Pembrolizumab Delivers Long-Term Benefits in ccRCC at Increased Risk of Recurrence @pennmedicine.bsky.social #SUO2025 #SUO25 #kcsm #oncology www.onclive.com/view/adjuvan...

NDV-01 Elicits 92% CR Rate in High-Risk NMIBC | OncLive Novel sustained-release NDV-01 achieved a 92% CR rate in high-risk patients with NMIBC with strong safety, supporting advancement to phase 3 studies.

NDV-01 Elicits 92% CR Rate in High-Risk NMIBC @utswtxid.bsky.social #SUO2025 #SUO25 #oncology www.onclive.com/view/ndv-01-...